CLSI and University of Edinburgh Partner to Address COVID-19
For the past three years, the California Life Sciences Institute (CLSI) has provided advisory support to the product development programs at the Queen’s Medical Research Institute (QMRI) at the University of Edinburgh. What began as a collaboration through CARB-X, the global partnership dedicated to supporting products to combat anti-microbial resistance, CLSI is now working with QMRI’s Centre for Inflammation Research on the STOPCOVID initiative to help develop therapeutics to save and rebuild the lives of COVID-19 patients.
COVID-19 kills when lungs become inflamed and the delicate lung tissues are destroyed. This sets off a cascade of processes that result in lung failure and the need for artificial ventilation. There is a critical time-point, however, before the need for ventilation, when treatment of the lung inflammation can prevent death. Even for patients who survive the virus, intensive care and ventilation may cause long-term physical and cognitive damage.
The University of Edinburgh is testing drugs that can be repurposed to treat lung disease. CLSI is using its networks to help find approved drugs that, individually or in combination, will be effective in patients with COVID-19. The goal of the initiative is to prevent deaths across the world and particularly in low-income countries where ventilation and intensive care are simply not available. At a time when the outlook looks bleak, this project is a very real opportunity to save lives. We welcome donations of compounds and/or funding to help drive our efforts. If you can help, please contact Steve Karp.